1. Retinoblastoma-Pipeline Review, H1 2016 Phone No.: +1 (214) 884-6817 Email id: sales@orbisresearch.com

2. Retinoblastoma-Pipeline Review, H1 2016 The report provides comprehensive information on the therapeutics under development for Retinoblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. Request a Sample of this Report @ http://www.orbisresearch.com/contacts/request-sample/144167. http://www.orbisresearch.com/contacts/request-sample/144167 Companies Mentioned Cellceutix Corporation Merck & Co., Inc. Novartis AG Onxeo SA Sumitomo Dainippon Pharma Co., Ltd. Taiwan Liposome Company, Ltd. Tiziana Life Sciences Plc Phone No.: +1 (214) 884-6817 Email id: sales@orbisresearch.com

3. About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors accross the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients. Contact Information: 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A. Phone No.: +1 (214) 884-6817 enquiry@orbisresearch.com sales@orbisresearch.com Phone No.: +1 (214) 884-6817 Email id: sales@orbisresearch.com Retinoblastoma-Pipeline Review, H1 2016